Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Indian Sun's generic AD drug

The US FDA has approved Indian company Sun Pharma's generic equivalent of Forest Laboratory's Alzheimer's disease treatment Namenda 

The US Food and Drug Administration (FDA) has approved Indian company Sun Pharma's Abbreviated New Drug Application (ANDA) to market a generic equivalent of Forest Laboratory's Alzheimer's disease (AD) treatment Namenda (memantine). Sun will receive 180 days of sales exclusivity on the drug which will be sold in 5mg and 10mg tablets.

The Mumbai-based company said that 5mg and 10mg strengths of memantine have combined annual sales of around $1.2bn in the US.

Memantine is the first in a novel class of Alzheimer's disease medications, which work by acting on the glutamatergic system, blocking NMDA glutamate receptors.

Memantine is also sold by Merz as Akatinol, by Lundbeck as Ebixa and Abixa and by Unipharm as Memox.

6th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics